Nyrada Inc.

NYR

AU0000070195

Pharmaceuticals

Market Closed - Australian S.E. Other stock markets 11:40:22 14/06/2024 am IST			5-day change	1st Jan Change
0.066 ^AUD	+4.76%		-8.33%	+200.00%

30/04	Nyrada's NYR-BI03 Being Studied For Potential in Traumatic Brain Injury	MT
18/04	Transcript : Nyrada Inc., Q3 2024 Earnings Call, Apr 18, 2024

Nyrada Inc. Announces Appointment of Marcus Frampton as Director

January 16, 2020 at 03:52 am IST

Nyrada Inc. announced the appointment of Marcus Frampton as Director. Date of appointment is 4 June 2019.

Latest news about Nyrada Inc.

Nyrada's NYR-BI03 Being Studied For Potential in Traumatic Brain Injury	30/04	MT
Transcript : Nyrada Inc., Q3 2024 Earnings Call, Apr 18, 2024	18/04
Transcript : Nyrada Inc. - Special Call	11/04
Nyrada Begins Animal Testing on NYR-BI03 Brain Injury Program	10/04	MT
Nyrada Begins Good Laboratory Practice Preclinical Study for Brain Injury Drug Candidate	28/03	MT
Nyrada Raises AU$1.8 Million via Placement	06/03	MT
Nyrada Inc. Reports Earnings Results for the Half Year Ended December 31, 2023	20/02	CI
Nyrada Secures AU$3.5 Million R&D Tax Rebate for Fiscal Year 2023; Shares Surge 30%	08/12	MT
Nyrada Inc. Reports Earnings Results for the Full Year Ended June 30, 2023	28/23/28	CI
Australian Shares Flat as June Unemployment Rate Remains at 3.5%	20/23/20	MT
Nyrada Halves Director Fees; Shares Jump 37%	20/23/20	MT
Nyrada Opts to Advance NYR-BI03 Brain Injury Drug Candidate	12/23/12	MT
Nyrada Completes Preclinical Studies on Cholesterol Lowering Medication	26/23/26	MT
Nyrada Completes Preclinical Dose Formulation for Cholesterol Lowering Medication	11/23/11	MT
Nyrada Inc. Reports Earnings Results for the Half Year Ended December 31, 2022	24/23/24	CI
Nyrada Extends R&D Deal for Brain Injury Drug Candidate	18/23/18	MT
Nyrada Inc. Announces Collaboration with Walter Reed and UNSW Extended to 2025	18/23/18	CI
Nyrada Advances Preclinical Studies for Brain Injury Drug Candidate	11/23/11	MT
Nyrada Inc. Provides Update on the Progress of Its Brain Injury Program	11/23/11	CI
Nyrada Receives $804,600 R&D Tax Refund; Shares fall 11%	18/22/18	MT
Nyrada Inc. Announces Efficacy Study Published in Journal of Lipid Research	10/22/10	CI
Nyrada Inc. Reports Earnings Results for the Full Year Ended June 30, 2022	29/22/29	CI
Nyrada Inc. Announces Board Changes	02/22/02	CI
Nyrada Validates Effectivity of Inhibitor Drug to Block Early Atherosclerosis; Shares Fall 6%	20/22/20	MT
Nyrada Delays Phase 1 Cholesterol Trial Due to Lockdown in China; Shares Fall 7%	29/22/29	MT

Nyrada Inc. is a preclinical stage, drug development company specializing in small molecule drugs to treat cardiovascular and neurological diseases. The Companyâs two lead programs are focused on cholesterol-lowering and brain injury. These programs are developing an oral, small molecule cholesterol-lowering drug, and a drug to reduce secondary brain damage following a stroke or traumatic brain injury (TBI). Its Cholesterol-Lowering Program is an oral PCSK9 inhibitor for the treatment of high blood LDL-cholesterol levels in patients poorly responsive to or unable to take statin drugs. Its Brain Injury Program is developing a drug to block secondary brain damage that occurs following a stroke or TBI, such as severe head trauma from contact sports, a fall, or a motor vehicle accident. The Brain Injury Program is a neuroprotectant drug to reduce the impact of long-term disability in patients who suffer a traumatic brain injury or ischemic stroke. It is also developing new therapies.

Sector

Pharmaceuticals

Calendar

26/08/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
NYRADA INC.	+200.00%	7.95M
NOVO NORDISK A/S	+41.96%	630B
JOHNSON & JOHNSON	-7.15%	350B
MERCK & CO., INC.	+18.77%	328B
ABBVIE INC.	+8.79%	298B
ASTRAZENECA PLC	+18.02%	246B
ROCHE HOLDING AG	+1.27%	225B
NOVARTIS AG	+11.95%	218B
AMGEN INC.	+3.68%	160B
PFIZER, INC.	-4.38%	156B